跳到主要导航 跳到搜索 跳到主要内容

Pulmonary Artery Denervation for Pulmonary Arterial Hypertension: A Sham-Controlled Randomized PADN-CFDA Trial

  • Hang Zhang
  • , Yongyue Wei
  • , Caojin Zhang
  • , Zhenwen Yang
  • , Jing Kan
  • , Heping Gu
  • , Fenling Fan
  • , Hong Gu
  • , Qiguang Wang
  • , Dujiang Xie
  • , Gangcheng Zhang
  • , Xiaomei Guo
  • , Yuehui Yin
  • , Bowen Jin
  • , Hongmei Zhou
  • , Ziyang Yang
  • , Zhouming Wang
  • , Yu Xin
  • , Chen Zhang
  • , Lili Meng
  • Xiaoyu Wang, Jingping Sun, Chunxia Zhao, Juan Zhang, Xiaoyan Yan, Feng Chen, Cheng Yao, Gregg W. Stone, Shao Liang Chen
  • The First Affiliated Hospital with Nanjing Medical University
  • Nanjing Medical University
  • Guangdong Academy of Medical Sciences
  • Tianjin Medical University
  • First Affiliated Hospital of Zhengzhou University
  • The First Affiliated Hospital of Xi’an Jiaotong University
  • Capital Medical University
  • Shenyang General Hospital of PLA
  • Zhongnan Hospital of Wuhan University
  • Huazhong University of Science and Technology
  • Chongqing Medical University
  • Wuhan Asia Heart Hospital
  • Peking University
  • Icahn School of Medicine at Mount Sinai

科研成果: 期刊稿件 › 文章 › 同行评审

70 引用 (Scopus)

摘要

Background: World Health Organization (WHO) group 1 pulmonary arterial hypertension (PAH) is a progressive, debilitating disease. Previous observational studies have demonstrated that pulmonary artery denervation (PADN) reduces pulmonary artery pressures in PAH. However, the safety and effectiveness of PADN have not been established in a randomized trial. Objectives: The aim of this study was to determine the treatment effects of PADN in patients with group 1 PAH. Methods: Patients with WHO group 1 PAH not taking PAH-specific drugs for at least 30 days were enrolled in a multicenter, sham-controlled, single-blind, randomized trial. Patients were assigned to receive PADN plus a phosphodiesterase-5 inhibitor or a sham procedure plus a phosphodiesterase-5 inhibitor. The primary endpoint was the between-group difference in the change in 6-minute walk distance from baseline to 6 months. Results: Among 128 randomized patients, those treated with PADN compared with sham had a greater improvement in 6-minute walk distance from baseline to 6 months (mean adjusted between-group difference 33.8 m; 95% CI: 16.7-50.9 m; P < 0.001). From baseline to 6 months, pulmonary vascular resistance was reduced by −3.0 ± 0.3 WU after PADN and −1.9 ± 0.3 WU after sham (adjusted difference −1.4; 95% CI: −2.6 to −0.2). PADN also improved right ventricular function, reduced tricuspid regurgitation, and decreased N-terminal pro–brain natriuretic peptide. Clinical worsening was less (1.6% vs 13.8%; OR: 0.11; 95% CI: 0.01-0.87), and a satisfactory clinical response was greater (57.1% vs 32.3%; OR: 2.79; 95% CI: 1.37-5.82) with PADN treatment during 6-month follow-up. Conclusions: In patients with WHO group 1 PAH, PADN improved exercise capacity, hemodynamic status, and clinical outcomes during 6-month follow-up.

源语言英语
页(从-至)2412-2423
页数12
期刊JACC: Cardiovascular Interventions
卷15
期23
DOI
出版状态已出版 - 12 12月 2022
已对外发布是

学术指纹

探究 'Pulmonary Artery Denervation for Pulmonary Arterial Hypertension: A Sham-Controlled Randomized PADN-CFDA Trial' 的科研主题。它们共同构成独一无二的学术指纹。

引用此